SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs > Peregrine Pharmaceuticals (PPHM)

Just to be clear, they didn't "let" options

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
cheynew Member Profile
Member Level 
Followed By 41
Posts 10,424
Boards Moderated 0
Alias Born 09/03/01
160x600 placeholder
Peregrine Pharmaceuticals Announces Promising Bavituximab Phase I Data Published in the Peer-Reviewed Journal Cancer Medicine... "GlobeNewswire Inc." - 3/31/2015 12:45:22 PM
Peregrine Pharma ups revenues 46% in FQ3 "Seeking Alpha" - 3/13/2015 7:26:55 AM
Peregrine Pharmaceuticals' (PPHM) CEO Steve King on Q3 2015 Results - Earnings Call Transcript "Seeking Alpha" - 3/12/2015 10:35:07 PM
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2015 Financial Results and Recent Developments "GlobeNewswire Inc." - 3/12/2015 4:00:00 PM
Independent Research Initiates Analyst Coverage on Inventergy Global, Inc. (NASDAQ: INVT) with $1.20 Price Target "InvestorsHub NewsWire" - 3/12/2015 8:00:00 AM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 3/10/2015 4:00:00 PM
Peregrine Pharmaceuticals to Report Third Quarter Fiscal 2015 Financial Results After Market on March 12, 2015 "GlobeNewswire Inc." - 3/5/2015 4:00:00 PM
Peregrine Pharmaceuticals to Present at the 27th Annual ROTH Conference "GlobeNewswire Inc." - 3/2/2015 4:00:00 PM
NEW CONCEPT LAUNCHES TODAY FOR MICRO-CAP STOCK TRADERS. RECEIVE PAID PRE-PROMO STOCK ALERTS FOR FREE. "InvestorsHub NewsWire" - 2/9/2015 7:00:00 AM
ALTITRADE PARTNERS™ SAYS A KEY-REVERSAL DAY COULD HAPPEN THIS WEEK "InvestorsHub NewsWire" - 10/14/2014 6:00:00 AM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "Marketwired" - 6/10/2014 4:00:00 PM
Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab & I... "Marketwired" - 4/23/2014 7:30:00 AM
Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Thera... "PR Newswire (US)" - 4/10/2014 12:28:00 PM
Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor & Immune... "Marketwired" - 4/9/2014 11:00:00 AM
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma "PR Newswire (US)" - 4/8/2014 1:15:00 PM
Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiati... "Marketwired" - 4/7/2014 8:00:00 AM
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting "Marketwired" - 4/1/2014 4:00:00 PM
cheynew Member Level  Thursday, 05/24/12 06:25:25 AM
Re: Threes post# 80517
Post # of 214069 
Just to be clear, they didn't "let" options expire. They were out of the money at the expiration date, so they died a natural death. They didn't take advantage of options at .46, the BOD awarded them. They have no cost until they are exercised, then they usually do a net sale transaction where they take the difference between the exercise price and the pps at the date of exercise. I hope they make a ton of money on these new options and the sooner the better.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist